The Zacks Analyst Blog Highlights: Carlyle Group, Blackstone Group, Kohlberg Kravis Roberts, Waddell & Reed Financial and GlaxoSmithKline
| PR Newswire Association LLC |
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Today,
Here are highlights from Wednesday's Analyst Blog:
Carlyle Group Making New Acquisition
In an attempt to diversify its business, The Carlyle Group LP (Nasdaq:CG-Free Report) recently announced that it will acquire
Carlyle will initially pay
Incepted in 2004, DGAM has roughly
The deal with DGAM will mark Carlyle's first venture into funds of hedge funds. However, the company already owns 55% stake in three regular hedge funds: credit specialist Claren Road Asset Management; emerging markets investor
Following the footsteps of asset manager Blackstone Group LP (NYSE:BX-Free Report) and Kohlberg Kravis Roberts & Co. L.P. (NYSE:KKR-Free Report), Carlyle has been diversifying its business over the past decade to grow assets and reduce greater dependence on leveraged buyouts. Carlyle recently acquired a 40% stake in Dutch investment manager
We believe that Carlyle's efforts to diversify beyond its traditional business will help to boost earnings amid a volatile operating environment. Also given its sound liquidity and balance sheet position, we expect the company to drive further inorganic growth in the quarters ahead.
Carlyle currently carries a Zacks Rank #3 (Hold). A better-ranked stocks in the same sector include Waddell & Reed Financial, Inc. (NYSE:WDR-Free Report), which carries a Zacks Rank #1 (Strong Buy).
Update on Glaxo's Avandia
GlaxoSmithKline's (NYSE:GSK-Free Report) Avandia is available for type II diabetes. Avandia came under the
In 2010, the
In
In
Of the 26-member panel, 13 voted in favor of modifying and 7 in favor of removing the Avandia REMS program. However, 5 members were in favor of continuing the REMS and 1 recommended removal of Avandia from the U.S. market.
We remind investors that the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial did not show an elevated risk of heart attack or death in patients being treated with Avandia versus standard diabetes therapies.
Today,
About
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from
About
Zacks.com is a property of
Get the full Report on CG - FREE
Get the full Report on BX - FREE
Get the full Report on KKR - FREE
Get the full Report on WDR - FREE
Get the full Report on GSK - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole.
SOURCE
| Wordcount: | 1206 |


Advisor News
- Survery: Most Americans still feel prosperous despite economic worries
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
More Advisor NewsAnnuity News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity NewsHealth/Employee Benefits News
- Health insurance switch costs city
- New LTC solutions fill a critical gap for clients
- HOMEOWNERS FACE SHRINKING COVERAGE WHILE HOME INSURERS RAKE IN RECORD PROFITS
- GOVERNOR HOCHUL TAKES ACTIONS TO PROTECT MEDICAID COVERAGE FOR NEARLY 2 MILLION NEW YORKERS
- Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
More Health/Employee Benefits NewsLife Insurance News
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- Nebraska widow’s big win against life insurer in legal limbo
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
More Life Insurance News